Recent advances in pathologic evaluation and reporting of melanoma.

abstract：:Identification of tumor-, patient-, or treatment-related prognostic factors in renal carcinoma (RC) would allow the most appropriate application of current and future therapy to patients with this poorly responsive malignancy. Stage, including degree of lymph node and venous involvement, and grade remain the most powe...

journal_title：Seminars in oncology

authors： Rini BI,Vogelzang NJ

更新日期：2000-04-01 00:00:00

abstract：:90Y ibritumomab tiuxetan (Zevalin; Biogen Idec Inc, Cambridge, MA), the first radioimmunotherapeutic agent approved by the US Food and Drug Administration, is a promising treatment option in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma, including patients wit...

journal_title：Seminars in oncology

authors： Gordon LI

更新日期：2003-12-01 00:00:00

abstract：:Patients with advanced colorectal cancer were randomized to receive either fluorouracil (5-FU) 370 mg/m2 IV days 1 to 5 followed by weekly applications of 5-FU 600 mg/m2 or the same doses of 5-FU preceded by folinic acid 200 mg/m2. Because of toxicity, the weekly 5-FU dose in the combination treatment schedule was red...

journal_title：Seminars in oncology

authors： Steinke B,Günther E,Hirschmann WD,Sondern W,Koniczek KH,Wander HE,Natt F,Wagner T,Hinrichs HF,Werdier D

更新日期：1992-04-01 00:00:00

abstract：:Because studies of breast cancer patients and their relatives provide statistical evidence for involvement of autosomal dominant genes, the identification of specific genetic effects has long been the focus of efforts to identify women at exceedingly high risk. BRCA1, a gene that confers greatly increased susceptibili...

journal_title：Seminars in oncology

authors： Cannon-Albright LA,Skolnick MH

更新日期：1996-02-01 00:00:00

abstract：:Approximately 60% of patients diagnosed with colorectal cancer (CRC) will go on to develop hepatic metastases. Although surgical resection is the only curative modality, a majority will not be able to undergo surgery. Alternative methods for treating this population have focused on the feasibility of hepatic arterial ...

journal_title：Seminars in oncology

authors： Dizon DS,Kemeny NE

更新日期：2002-04-01 00:00:00

abstract：:Patients with acute myeloid leukemia and acute lymphocytic leukemia receive significant numbers of blood products for hematologic support during periods of disease and treatment related cytopenias. These patients may be at increased risk for complications associated with transfusion. This article reviews the indicatio...

journal_title：Seminars in oncology

authors： Webb IJ,Anderson KC

更新日期：1997-02-01 00:00:00

abstract：:Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and in...

journal_title：Seminars in oncology

authors： Pantuck AJ,Thomas G,Belldegrun AS,Figlin RA

更新日期：2006-10-01 00:00:00

abstract：:The optimal management of early stage ovarian cancer with poor prognostic features remains controversial. On the basis of results of studies in advanced ovarian cancer, paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) in combination with a platinum agent has become part of adjuvant chemotherapy trials i...

journal_title：Seminars in oncology

authors： Young RC

更新日期：2000-06-01 00:00:00

abstract：:Lymphomas of the head and neck arise in Waldeyer's ring, the salivary glands, nasal cavity, paranasal sinuses, thyroid gland, and orbit. Though anatomically in close proximity, lymphomas arising in these sites have distinct clinical characteristics. Factors that appear to influence the pattern of disease include concu...

journal_title：Seminars in oncology

authors： Yuen A,Jacobs C

更新日期：1999-06-01 00:00:00

abstract：:Session IV of the Second International Colloquium on Cardio-Oncology held in Kraków, focused on the cardiovascular risks of using hormone replacement therapy in breast cancer and androgen deprivation therapy in prostate cancer and continued the theme from Session 3 with a discussion of risk reduction strategies. The d...

journal_title：Seminars in oncology

authors： Plummer C,Steingart RM,Jurczak W,Iakobishvili Z,Lyon AR,Plastaras JP,Minotti G

更新日期：2019-12-01 00:00:00

abstract：:The recommended weekly dose and the maximum tolerated weekly dose of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) have yet to be determined. We report that a weekly dose of up to 40 mg/m2 docetaxel for 6 weeks is active in pretreated patients with metastatic breast cancer. From a preliminary study, this d...

journal_title：Seminars in oncology

authors： Löffler TM

更新日期：1998-10-01 00:00:00

abstract：:Prostate cancer (PC) is the most prevalent malignancy in men, with 604,506 new cases diagnosed yearly worldwide. Maintaining bone health is important during all stages of PC, including patients who experience bone loss from androgen-deprivation therapy and patients who develop bone metastases. Patients with bone metas...

journal_title：Seminars in oncology

authors： Saad F,Eastham J

更新日期：2010-06-01 00:00:00

abstract：:Ten years of interferon (IFN) therapy have followed the approval of this agent by the US Food and Drug Administration on June 5, 1986. As the first biotherapeutic approved, IFN-alpha paved the way for the many new biotherapeutics. Regardless of this long history, however, we have just touched the surface of understand...

journal_title：Seminars in oncology

authors： Pestka S

更新日期：1997-06-01 00:00:00

abstract：:Blast crisis terminates the life of the majority (approximately 80%) of patients with CML. The time of its onset appears to be a random phenomenon, varying from a probable coincidence occurrence with the onset of CML to more than a decade after onset of the chronic phase. In most patients the diagnosis is obvious as v...

journal_title：Seminars in oncology

authors： Boggs DR

更新日期：1976-09-01 00:00:00

abstract：:Carcinoma of the bladder is the most prevalent cancer in Egypt and in most African countries. At the National Cancer Institute (NCI), Cairo, it constitutes 30.3% of all cancers. The median age at diagnosis is 46 years, with a male preponderance of 5:1. Whether in Egypt or other African countries such as Sudan, Kenya, ...

journal_title：Seminars in oncology

authors： el-Mawla NG,el-Bolkainy MN,Khaled HM

更新日期：2001-04-01 00:00:00

abstract：:Transitional cell carcinoma of the urothelium is a highly chemosensitive tumor. Combination chemotherapy can provide both palliation and a modest survival advantage in patients with advanced disease. As shown in a recent phase III trial, the new gold standard should be considered gemcitabine/cisplatin, although toxici...

journal_title：Seminars in oncology

authors： Carles J,Nogué M

更新日期：2001-06-01 00:00:00

abstract：:Cancer cells that express excessive levels of Bcl-2 pose a major problem in the delivery of curative therapy. Most treatments for such cancer involve chemotherapy to induce the apoptotic process. While these therapies often result in disease control for periods of time, failure to initiate apoptosis as a result of acq...

journal_title：Seminars in oncology

authors： Cotter FE

更新日期：2004-12-01 00:00:00

abstract：:The current study was conducted to determine the risk of adverse outcomes among patients with monoclonal gammopathy of undetermined significance (MGUS) of the IgM class. Two hundred thirteen patients with IgM MGUS were identified in southeastern Minnesota from 1960 to 1994. The primary end point was progression to lym...

journal_title：Seminars in oncology

authors： Kyle RA,Therneau TM,Rajkumar SV,Offord JR,Larson DR,Plevak MF,Melton LJ 3rd

更新日期：2003-04-01 00:00:00

abstract：:Adrenocortical cancer (ACC) is a rare, challenging disease with a broad range of clinical presentations. Often presenting in an advanced stage with a large, locally invasive primary tumor or with Cushing's syndrome, it requires a multidisciplinary approach to treatment. We discuss controversies in the evaluation and m...

journal_title：Seminars in oncology

authors： Balasubramaniam S,Fojo T

更新日期：2010-12-01 00:00:00

abstract：:Preliminary clinical studies demonstrated that 5' nor-anhydro-vinblastine, Navelbine (NVB) has a broader antitumor activity and fewer neurotoxic effects than vinblastine or vincristine. The tectal plate anlage of mouse embryos at the earliest stages of neuronal differentiation were used to analyze and compare the effe...

journal_title：Seminars in oncology

authors： Binet S,Fellous A,Lataste H,Krikorian A,Couzinier JP,Meininger V

更新日期：1989-04-01 00:00:00

abstract：:Recent improvements in the management of people living with human immunodeficiency virus (HIV) disease in the United States have led to remarkable reductions in HIV-related morbidity and mortality. The Centers for Disease Control and Prevention recently reported substantial reductions in acquired immunodeficiency synd...

journal_title：Seminars in oncology

authors： Sherer R

更新日期：1998-04-01 00:00:00

abstract：:Although chemotherapy for advanced bladder cancer has historically been based on cisplatin-based combination regimens, the limitations of these regimens both in terms of efficacy and toxicity are now widely appreciated. In response to these limitations, other single agents have been studied, and a number have demonstr...

journal_title：Seminars in oncology

authors： Roth BJ

更新日期：1996-06-01 00:00:00

abstract：:Multitargeted antifolate (MTA, LY231514) is a novel antifolate antimetabolite, with antitumor activity via inhibition of thymidylate synthase, glycinamide formyl transferase, and dihydrofolate reductase. Three dosing schedules have been investigated in the phase I setting: daily x5 every 21 days, weekly x4 every 42 da...

journal_title：Seminars in oncology

authors： Rinaldi DA

更新日期：1999-04-01 00:00:00

abstract：:Non-small cell lung cancer (NSCLC) remains a malignancy that is refractory to most currently available chemotherapeutic agents. The most frequently used systemic therapy is cisplatin-based combination therapy, which is not always suitable for patients with stage IV disease because of toxicity. Thus, any single agent w...

journal_title：Seminars in oncology

authors： Manegold C

更新日期：1998-08-01 00:00:00

abstract：:Expanding knowledge about basic biology and a detailed understanding of the signaling pathways that participate in the growth and metastasis of breast cancer have identified opportunities for diagnostic and therapeutic intervention. Endocrine therapy represents the first and most successful example of targeted therapy...

journal_title：Seminars in oncology

authors： Hortobagyi GN

更新日期：2004-02-01 00:00:00

abstract：:A phase I/II study was conducted to determine the response rate and the toxicity of escalating doses of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) plus cisplatin with granulocyte colony-stimulating factor support in patients with untreated advanced head and neck carcinoma. Twenty-eight patients wi...

journal_title：Seminars in oncology

authors： Hitt R,Paz-Ares L,Hidalgo M,Colomer R,Brandariz A,Peña M,Alvarez-Vicent J,Hornedo J,Cortés-Funes H

更新日期：1997-12-01 00:00:00

abstract：:Single-agent docetaxel has been shown to produce a significant decrease in prostate-specific antigen (PSA) levels among patients with hormone-refractory prostate cancer (HRPC). A recent study also showed that exisulind, a sulfone metabolite of the nonsteroidal anti-inflammatory drug sulindac, lengthens the median PSA ...

journal_title：Seminars in oncology

authors： Ryan CW,Stadler WM,Vogelzang NJ

更新日期：2001-08-01 00:00:00

abstract：:Predicting which patients with primary melanoma are at risk of developing metastastic disease is important for making rational therapeutic decisions. Tumor thickness alone is the most commonly used predictor of survival, but other clinical and pathologic variables also play an important role. We have developed two mul...

journal_title：Seminars in oncology

authors： Halpern AC,Schuchter LM

更新日期：1997-02-01 00:00:00

abstract：:Studies in vitro and in animal models have helped define the mechanism of action of antiestrogens and the differences in the physical properties of the various antiestrogens. Tamoxifen is the most widely studied antiestrogen. A review of 45 separate studies has shown a response rate to tamoxifen in advanced breast can...

journal_title：Seminars in oncology

authors： Lippman ME

更新日期：1983-12-01 00:00:00

abstract：:Because patients with metastatic bone disease suffer a significant burden from their illness and from anticancer treatments, it is therefore important to minimize the side effects of bisphosphonates. The intravenous bisphosphonates, zoledronic acid and pamidronate, have tolerability issues that include a flu-like synd...

journal_title：Seminars in oncology

authors： Body JJ,Diel I,Bell R

更新日期：2004-10-01 00:00:00